Cliff Holloway

Cliff Holloway has a diverse and extensive work experience in biotechnology and investment. Currently, they hold the position of Chief Business Officer at Ethris, a company specializing in mRNA design and delivery. Prior to that, they worked as Director at Newstar Ventures, an investment fund focused on the biotech industry.

Cliff also served as the Chief Executive Officer at Scancell Holdings PLC, where they contributed to the development of novel cancer treatments. Before that, they served as the Chief Business and Operating Officer at Benitec Biopharma, working on therapeutics for various medical needs.

Earlier in their career, Holloway held executive positions at companies such as Sienna Cancer Diagnostics, Immune System Therapeutics Ltd, and Biosceptre International, where they contributed to the development of diagnostic technologies and antibody-based cancer treatments.

Additionally, they have experience in business development, as evidenced by their role as Vice President of Business Development at Arana Therapeutics. Holloway's early work experience includes serving as Vice President of Asia Pacific Operations at Superscape Group.

Overall, Cliff Holloway's work experience demonstrates their expertise in biotech investment, business development, and leadership in the development of innovative therapeutic approaches for cancer and other medical conditions.

Cliff Holloway completed their Bachelor of Pharmacy (Honors) degree in Pharmacy at the University of Nottingham from 1978 to 1981. Cliff further pursued their education at the same institution and obtained a Ph.D. in Medicinal Chemistry from 1982 to 1985.